Breast Cancer

Fowble, Barbara; Park, Catherine; Yuen, Florence

doi:10.1007/978-3-319-31460-0_7

Cited by 3 publications

(3 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) toxicity criteria and National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) systems are the most commonly used ( Table 2 ). 4 , 36 , 37…”

Section: Assessment and Scoringmentioning

confidence: 99%

“…A large proportion of breast cancer patients receive adjuvant radiation therapy (RT) in either the breast conservation or the postmastectomy setting to improve locoregional recurrence rates and overall survival 2,3. Patients undergoing RT to the intact breast or chest wall with or without regional lymph nodes typically receive 4–6 weeks of treatment, with radiation dermatitis anticipated as the most common acute side effect 4,5. This review focuses on the causes of radiation dermatitis, summarizes the preventative measures, and discusses the strategies for the management of radiation-related skin toxicity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Acute radiation dermatitis in breast cancer patients: challenges and solutions

Kole¹,

Kole²,

Moran³

2017

BCTT

102

106

View full text Add to dashboard Cite

Nearly all women who receive radiotherapy (RT) for breast cancer experience some degree of radiation dermatitis. However, evidence describing the appropriate management of radiation dermatitis is often lacking or contradictory. Here, we summarize the available literature regarding radiation dermatitis causes, the presentation and timing of symptoms, methods for dermatitis assessment and prevention, and review evidence-based management strategies.

show abstract

Section: Assessment and Scoringmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Acute radiation dermatitis in breast cancer patients: challenges and solutions

Kole¹,

Kole²,

Moran³

2017

BCTT

102

106

View full text Add to dashboard Cite

show abstract

“…The severity of radiodermatitis has been graded by the National Cancer Institute (USA) into four levels: Grade 1 (mild erythema or desquamation), grade 2 (moderate erythema and moist desquamation confined to skin folds and creases), grade 3 (confluent moist desquamation greater than 1.5cm diameter which is not confined to skin folds possibly with pitting oedema) and grade 4 (skin necrosis or ulceration of full thickness of the dermis). 4 , 5…”

Section: Introductionmentioning

confidence: 99%

<p>A Fibroblast-Derived Human Growth Factor Preparation for the Management of Acute Radiodermatitis: A Case Report</p>

Vadarli¹,

Angelo-Khattar²

2020

IMCRJ

View full text Add to dashboard Cite

Radiotherapy is a commonly used modality in breast cancer management. Amongst the consequences of treatment are acute and/or chronic skin changes, which often lead to itching, pain, and a diminished aesthetic appearance, all of which greatly impact the patient’s quality of life. Management of radiation-induced skin effects has not as yet been standardized, with various protocols being applied by different radiotherapy departments. This case study outlines the management of a grade 3 acute radiodermatitis in a female with a synergistic preparation of anti-inflammatory cytokines and growth factors derived from human fibroblasts. The treatment resulted in the total resolution of the radiation-induced skin reaction, with a minimally visible residual scar.

show abstract

Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial

Wolf

Gewandter

Bautista

et al. 2019

Support Care Cancer

View full text Add to dashboard Cite

Purpose-Although topical agents are often provided during radiation therapy, there is limited consensus and evidence for their use prophylactically to prevent or reduce radiation dermatitis. Methods-This was a multi-site, randomized, placebo-controlled, blinded study of 191 breast cancer patients to compare the prophylactic effectiveness of three topical agents (Curcumin, HPR Plus™, and Placebo) for reducing radiation dermatitis and associated pain. Patients applied the topical agent to their skin in the radiation area site three times daily starting the first day of radiation therapy (RT) until 1 week after RT completion. Results-Of the 191 randomized patients, 171 patients were included in the final analyses (87.5% white females, mean age = 58 (range = 36-88)). Mean radiation dermatitis severity (RDS) scores did not significantly differ between study arms (Curcumin = 2.68 [2.49, 2.86]; HPR Plus™ = 2.64 [2.45, 2.82]; Placebo = 2.63 [2.44, 2.83];p = 0.929). Logistic regression analyses showed Julie Ryan Wolf,

show abstract

Breast Cancer

Cited by 3 publications

References 126 publications

Acute radiation dermatitis in breast cancer patients: challenges and solutions

Acute radiation dermatitis in breast cancer patients: challenges and solutions

<p>A Fibroblast-Derived Human Growth Factor Preparation for the Management of Acute Radiodermatitis: A Case Report</p>

Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial

Contact Info

Product

Resources

About